An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors Grifols
- 13 Feb 2018 Status changed from recruiting to completed.
- 26 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 18 Nov 2015 New trial record